Absci enters collab with AstraZeneca to advance AI-driven oncology candidate

Absci (ABSI) announced a collaboration with AstraZeneca (AZN), a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci’s Integrated Drug Creation platform with AstraZeneca’s expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. Absci will contribute its pioneering generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales. “AstraZeneca is a leader in developing novel treatments in oncology, and we are excited to collaborate with them to design a therapeutic candidate antibody with the potential to improve the lives of cancer patients,” said Sean McClain, Absci Founder & CEO. “This agreement advances Absci’s goal of creating a new generation of life-changing and transformative therapeutics using its AI platform.”